Trials / Completed
CompletedNCT02001181
Tofacitinib Ointment For Atopic Dermatitis (Atopic Eczema)
A Phase 2a, Multi-site, Randomized, Double-blind, Vehicle-controlled, Parallel-group Study Of The Pilot Efficacy, Safety, Tolerability, And Pharmacokinetics Of 2% Tofacitinib Ointment In Subjects With Mild To Moderate Atopic Dermatitis
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 69 (actual)
- Sponsor
- Pfizer · Industry
- Sex
- All
- Age
- 18 Years – 60 Years
- Healthy volunteers
- Not accepted
Summary
The study is being conducted to evaluate the efficacy, safety and tolerability of 2% tofacitinib ointment (20 mg/g) BID (twice daily) in subjects with mild to moderate atopic dermatitis compared to placebo (vehicle) BID for 4 weeks.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Tofacitinib ointment 20mg/g | Tofacitinib ointment 20mg/g twice daily (BID) for 4 weeks |
| DRUG | Placebo ointment (Vehicle) | Placebo ointment (vehicle) twice daily (BID) for 4 weeks |
Timeline
- Start date
- 2013-12-01
- Primary completion
- 2014-09-01
- Completion
- 2014-09-01
- First posted
- 2013-12-04
- Last updated
- 2015-10-15
- Results posted
- 2015-10-15
Locations
5 sites across 1 country: Canada
Source: ClinicalTrials.gov record NCT02001181. Inclusion in this directory is not an endorsement.